Neuroendocrine differentiation in castration-resistant prostate cancer: A systematic diagnostic attempt

Clinical Genitourinary Cancer

Volumn 10, Issue 3, 2012, Pages 164-173

  Matei, Deliu Victor ^a   Renne, Giuseppe ^a   Pimentel, Marcelo ^b   Sandri, Maria Teresa ^a   Zorzino, Laura ^a   Botteri, Edoardo ^a   De Cicco, Concetta ^a   Musi, Gennaro ^a   Brescia, Antonio ^a   Mazzoleni, Federica ^a   Tringali, Valeria ^a   Detti, Serena ^a   De Cobelli, Ottavio ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Hospital da Cidade de Passo Fundo   (Brazil)

Author keywords

Castration resistant prostate cancer; Neuroendocrine differentiation; Octreotide scintigraphy; Plasma chromogranin A; Somatostatin analogues; Tissular chromogranin A

Indexed keywords

ANDROGEN RECEPTOR; CHROMOGRANIN A; KI 67 ANTIGEN; PENTETREOTIDE IN 111; PROSTATE SPECIFIC ANTIGEN; SOMATOSTATIN RECEPTOR 2; TISSULAR CGA; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; NEUROENDOCRINE DIFFERENTIATION; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PHENOTYPE; PREVALENCE; PROTEIN BLOOD LEVEL; REPRODUCIBILITY; TUMOR DIFFERENTIATION; TUMOR SCINTISCANNING;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHROMOGRANIN A; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NEUROENDOCRINE TUMORS; ORCHIECTOMY; PROSTATE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECEPTORS, SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84865030764     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2011.12.004     Document Type: Article

References (52)

1. A. Sciarra, G. Mariotti, V. Gentile Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU Int 91 2003 438 445 (Pubitemid 36359624)
2. A. Komiya, H. Suzuki, T. Imamoto Neuroendocrine differentiation in the progression of prostate cancer Int J Urol 16 2009 37 44
3. N. Vashchenko, P.A. Abrahamsson Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities Eur Urol 47 2005 147 155 (Pubitemid 40126970)
4. P.A. Abrahamsson Neuroendocrine differentiation in prostatic carcinoma Prostate 39 1999 135 148
5. R. Casella, L. Bubendorf, G. Sauter Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies J Urol 160 1998 406 410 (Pubitemid 29476688)
6. A. Angelsen, U. Syversen, O.A. Haugen Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 30 1997 1 6 (Pubitemid 27053534)
7. D. Hirano, Y. Okada, S. Minei Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy Eur Urol 45 2004 586 592 discussion 92 (Pubitemid 38481685)
8. A. Sciarra, F. Di Silverio, A.M. Autran Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma Urol Int 82 2009 147 151
9. V.E. Theodoropoulos, A. Tsigka, A. Mihalopoulou Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications Urology 66 2005 897 902 (Pubitemid 41440864)
10. P.A. di Sant'agnese Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments Ann Oncol 12 suppl 2 2001 S135 S140
11. E. Bollito, A. Berruti, M. Bellina Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma Ann Oncol 12 suppl 2 2001 S159 S164 Suppl 2
12. H. Kokubo, Y. Yamada, Y. Nishio Immunohistochemical study of chromogranin A in stage D2 prostate cancer Urology 66 2005 135 140 (Pubitemid 41002202)
13. A. Cabrespine, L. Guy, F. Gachon Circulating chromogranin A and hormone refractory prostate cancer chemotherapy J Urol 175 2006 1347 1352
14. H. Bonkhoff, R. Berges From pathogenesis to prevention of castration resistant prostate cancer Prostate 70 2010 100 112
15. I.F. Tannock, R. de Wit, W.R. Berry Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
16. D.P. Petrylak, C.M. Tangen, M.H. Hussain Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520 (Pubitemid 39315318)
17. A. Stangelberger, A.V. Schally, B. Djavan New treatment approaches for prostate cancer based on peptide analogues Eur Urol 53 2008 890 900
18. A. Sciarra, A. Cardi, C. Dattilo New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma Int J Clin Pract 60 2006 462 470
19. M.E. Taplin, D.J. George, S. Halabi Prognostic significance of plasma chromogranin A levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study Urology 66 2005 386 391 (Pubitemid 41138103)
20. A. Berruti, A. Mosca, M. Tucci Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease Endocr Relat Cancer 12 2005 109 117 (Pubitemid 40477092)
21. A. Berruti, E. Bollito, C.M. Cracco The prognostic role of immunohistochemical chromogranin A expression in prostate cancer patients is significantly modified by androgen-deprivation therapy Prostate 70 2010 718 726
22. E. Ishida, M. Nakamura, K. Shimada Immunohistochemical analysis of neuroendocrine differentiation in prostate cancer Pathobiology 76 2009 30 38
23. A. Heidenreich, G. Aus, M. Bolla EAU guidelines on prostate cancer Eur Urol 53 2008 68 80 (Pubitemid 350166735)
24. G. Spitaleri, D.V. Matei, G. Curigliano Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer Ann Oncol 20 2009 498 502
25. A. Sciarra, V. Panebianco, M. Ciccariello Complete response to the combination therapy with androgen blockade and somatostatin analogue in a patient with advanced prostate cancer: magnetic resonance imaging with 1H-spectroscopy Eur Urol 53 2008 652 655 (Pubitemid 351178981)
26. C. Cerulli, A. Sciarra, G. Salvatori Long-term response to combination therapy with estramustine and somatostatin analogue in a patient with androgen ablation-refractory prostate cancer Urology 64 2004 e1 e3
27. A. Sciarra, C. Bosman, G. Monti Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma J Urol 172 5 Pt 1 2004 1775 1783 (Pubitemid 39363055)
28. F. Di Silverio, A. Sciarra Combination therapy of ethinylestradiol and somatostatin analogue reintroduces objective clinical responses and decreases chromogranin A in patients with androgen ablation refractory prostate cancer J Urol 170 2003 1812 1816 (Pubitemid 37254934)
29. L.J. Deftos, S. Nakada, D.W. Burton Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate Urology 48 1996 58 62 (Pubitemid 26255959)
30. T. Sasaki, A. Komiya, H. Suzuki Changes in chromogranin A serum levels during endocrine therapy in metastatic prostate cancer patients Eur Urol 48 2005 224 229 discussion, 9-30 (Pubitemid 40957093)
31. N. Segawa, I. Mori, H. Utsunomiya Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer Pathol Int 51 2001 452 459 (Pubitemid 32646211)
32. G. Ahlgren, K. Pedersen, S. Lundberg Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment Prostate 42 2000 274 279 (Pubitemid 30104570)
33. T. Jiborn, A. Bjartell, P.A. Abrahamsson Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment Urology 51 1998 585 589 (Pubitemid 28186211)
34. A. Berruti, A. Mosca, F. Porpiglia Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease J Urol 178 3 Pt 1 2007 838 843 Quiz 1129 (Pubitemid 47211059)
35. J. Huang, J.L. Yao, P.A. di Sant'agnese Immunohistochemical characterization of neuroendocrine cells in prostate cancer Prostate 66 2006 1399 1406 (Pubitemid 44350365)
36. J. Jongsma, M.H. Oomen, M.A. Noordzij Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines Prostate 42 2000 34 44 (Pubitemid 30004873)
37. R. Grobholz, M. Griebe, C.G. Sauer Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma Hum Pathol 36 2005 562 570 (Pubitemid 40776010)
38. C.D. Chen, D.S. Welsbie, C. Tran Molecular determinants of resistance to antiandrogen therapy Nat Med 10 2004 33 39 (Pubitemid 38524696)
39. E.C. Nelson, A.J. Cambio, J.C. Yang Clinical implications of neuroendocrine differentiation in prostate cancer Prostate Cancer Prostatic Dis 10 2007 6 14 (Pubitemid 46358906)
40. A. Berruti, L. Dogliotti, A. Mosca Circulating neuroendocrine markers in patients with prostate carcinoma Cancer 88 2000 2590 2597 (Pubitemid 30331968)
41. T. Fixemer, K. Remberger, H. Bonkhoff Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma Prostate 53 2002 118 123
42. Y. Sun, J. Niu, J. Huang Neuroendocrine differentiation in prostate cancer Am J Transl Res 1 2009 148 162
43. M.K. Cohen, D.A. Arber, K.S. Coffield Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression Cancer 74 1994 1899 1903 (Pubitemid 24301851)
44. R.W. Veltri, S. Isharwal, M.C. Miller Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis Prostate 68 2008 1806 1815
45. G. Ahlegren, K. Pedersen, S. Lundberg Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume Urology 56 2000 1011 1015
46. Y. Yamada, K. Nakamura, S. Aoki An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancer BJU Int 99 2007 189 195 (Pubitemid 44915645)
47. E.P. Krenning, D.J. Kwekkeboom, W.H. Bakker Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients Eur J Nucl Med 20 1993 716 731 (Pubitemid 23284773)
48. J.C. Reubi, H.R. Maecke Peptide-based probes for cancer imaging J Nucl Med 49 2008 1735 1738
49. S. Nilsson, J.C. Reubi, K.M. Kalkner Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy Cancer Res 55 23 suppl 1995 5805s 5810s
50. K.M. Kalkner, S. Acosta, O. Thorsson Octreotide scintigraphy and chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormone-refractory prostate cancer Prostate Cancer Prostatic Dis 9 2006 92 98 (Pubitemid 43378876)
51. M. Mencobonii, S. Tredici, L. Rebella Effect of chemotherapy on somatostatin receptor detection with octreotide scintigraphy in hormone-refractory prostate cancer patients Anticancer Res 26 2006 2233 2235 (Pubitemid 43980178)
52. M.P. Roudier, L.D. True, C.S. Higano Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone Hum Pathol 34 2003 646 653 (Pubitemid 36875509)